Preexisting opioid use disorder is associated with poor outcomes in hospitalized acute pancreatitis patients. Issue 11 (November 2021)

• Record Type: Journal Article
• Authors: Shaikh, Abdullah S.; Al Mouslmani, Mhd Yassin; Raza Shah, Aun; Hassan Khan, Zarak; Tausif Siddiqui, Mohamed; Saraireh, Hamzeh; Chandan, Saurabh; Umar, Shifa; Arora, Sumant; Desai, Madhav; Guturu, Praveen; Bilal, Mohammad
• Is Part Of: European journal of gastroenterology & hepatology. Volume 33:Issue 11(2021)
• Publication Date: 2021-11
• Subjects: acute pancreatitis -- healthcare utilization -- opioid epidemic -- pioid use disorder -- pancreatitis; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Digestive organs -- Diseases; Liver -- Diseases; Periodicals; 616.33
• DOI: 10.1097/MEG.0000000000002265
• Languages: English
• ISSNs: 0954-691X

Abstract

Abstract : Introduction: Although opioids are widely used for pain management in acute pancreatitis, the impact of opioid use disorder (OUD) on outcomes in patients with acute pancreatitis remains unknown. In the current study, we aimed to evaluate the impact of the OUD on outcomes in patients hospitalized with acute pancreatitis and delineate the trends associated with OUD and acute pancreatitis using a nationally representative sample. Methods: This is a retrospective cohort study of patients with acute pancreatitis using the combined releases of the year 2005–2014 of the National (Nationwide) Inpatient Sample ( NIS ) database. Patients over the age of 18 years with a principal diagnosis of acute pancreatitis were divided into cohorts of patients with opioid use disorders and those without. The primary measured outcome was in-hospital mortality and secondary outcomes were healthcare utilization measures, including length of stay (LOS) and hospitalization costs. Results: A total of 2 593 831 hospitalizations of acute pancreatitis were included; of which, 37 849 (1.46%) had a secondary diagnosis of OUD. Total acute pancreatitis-related hospitalizations increased from 237 882 in 2005 to 274 006 in 2014. At the same time prevalence of OUD in acute pancreatitis patients also increased from 1 to 2.1%. Patients with OUD had significantly increased mortality as compared to patients without OUD (aOR: 1.4; P < 0.001). At the same time, acute pancreatitis patients with OUD were associated with 1.3 days longer LOS as compared to other acute pancreatitis patients ( P < 0.001]. The mean adjusted difference in total hospitalization costs was $2353 ( P < 0.001). Conclusion: OUD is associated with a significant increase in LOS, healthcare utilization cost and in-hospital mortality in patients admitted for acute pancreatitis. Therefore, clinicians should exercise caution in prescribing opioid medications to this high-risk patient population and other modalities such as nonopioid pain medications should be tried as alternatives to opioid analgesics. Abstract : Supplemental Digital Content is available in the text.